Alto Neuroscience (NYSE:ANRO) Stock Price Up 7.6% - Time to Buy?

Key Points

• Alto Neuroscience shares rose 7.6% to about $33.52, while trading volume was 70% below the average session volume.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $37.88; ratings range from Buy to Sell.
• The company reported a quarterly loss of $0.54 per share, beating analysts’ estimate of a $0.67 loss per share.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) traded up 7.6% during trading on Thursday. The company traded as high as $32.52 and last traded at $33.5160. 131,380 shares changed hands during trading, a decline of 70% from the average session volume of 432,147 shares. The stock had previously closed at $31.15.

Analysts Set New Price Targets

Several brokerages recently weighed in on ANRO. Wall Street Zen lowered Alto Neuroscience from a "hold" rating to a "sell" rating in a report on Saturday, September 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. Wedbush increased their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a research report on Thursday, August 13th. BTIG Research reiterated a "buy" rating and set a $37.00 target price on shares of Alto Neuroscience in a research report on Wednesday. Finally, Zacks Research upgraded shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 20th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and an average price target of $37.88.

Alto Neuroscience Stock Up 3.9%

The stock has a fifty day simple moving average of $26.63 and a two-hundred day simple moving average of $24.50. The firm has a market cap of $1.27 billion, a PE ratio of -13.26 and a beta of 1.42. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.54) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.13. As a group, sell-side analysts expect that Alto Neuroscience, Inc. will post -2.69 EPS for the current fiscal year.

Insider Transactions at Alto Neuroscience

In other Alto Neuroscience news, CFO Nicholas Smith sold 24,056 shares of the firm's stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the completion of the transaction, the chief financial officer directly owned 24,060 shares of the company's stock, valued at $621,229.20. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.25% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Commodore Capital LP grew its position in Alto Neuroscience by 49.4% during the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company's stock worth $61,217,000 after buying an additional 900,000 shares in the last quarter. Perceptive Advisors LLC raised its holdings in shares of Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company's stock valued at $45,182,000 after acquiring an additional 225,500 shares in the last quarter. Spruce Street Capital LP boosted its position in shares of Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company's stock valued at $29,116,000 after acquiring an additional 1,102,366 shares during the last quarter. Affinity Asset Advisors LLC bought a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $11,240,000. Finally, Jennison Associates LLC bought a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $8,687,000.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto's approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.